Endothelial progenitor cell therapy - Allife Medical Science and Technology
Alternative Names: iPSC EPCs - Allife Medical Science and TechnologyLatest Information Update: 25 Apr 2024
At a glance
- Originator Allife Medical Science and Technology
- Class Cardiovascular therapies; Stem cell therapies
- Mechanism of Action Bone marrow cell stimulants; Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Chronic limb-threatening ischemia
- Preclinical Stroke
Most Recent Events
- 11 Apr 2024 Phase-I clinical trials in Chronic limb threatening ischemia (Treatment-naive) in China (IV) (NCT06359912)
- 24 Aug 2023 Preclinical trials in Stroke in China (IV) (NCT05993884)
- 24 Aug 2023 Allife Medical Science and Technology plans a phase I trial for Stroke (In adults, In the elderly) in China (IV)(NCT05993884)